No Detail Found!

Role of Betatrophin and In ammation Markers in Type 2 Diabetes Mellitus, Prediabetes and Metabolic Syndrome

Author(s)
Erhan Onalan Department of Internal Medicine, Firat University Medical School,Elazig,Turkey
Ahmet Bozkurt Department of Internal Medicine, Firat University Medical School,Elazig,Turkey
Mehmet Ferit Gursu Department of Medical Biochemistry and Clinical Biochemistry, Firat University Medical School,Elazig,Turkey
Burkay Yakar Department of Family Medicine, Firat University, Medical School,Elazig,Turkey
Emir Donder Department of Internal Medicine, Firat University Medical School,Elazig,Turkey
Abstract
Objective: To determine the association of betatrophin and in ammation factors in metabolic diseases such as diabetes, impaired fasting glucose, impaired glucose tolerance and metabolic syndrome. Study Design: A cross-sectional, analytical study. Place and Duration of Study: F1rat University Medical School between April 2017 and December 2020. Methodology: The study included 20 patients with type 2 diabetes mellitus, 20 patients with impaired fasting glucose (IFG), 20 patients with impaired glucose tolerance (IGT), 20 patients with metabolic syndrome (MetS), and a control group consisting of 20 healthy individuals. Anthropometric, fasting serum biochemical data were collected. Circulating betatrophin, and in ammation markers were measured by enzyme-linked immunosorbent assay (ELISA). The association of betatrophin, TNF-alpha, and IL-6 levels between groups were performed with One-way ANOVA and post-hoc Tukey HSD test. Results: Signi cantly higher levels of circulating betatrophin were observed in IFG, IGT, And MetS groups compared to healthy controls (p=0.017). There were signi cantly di erence TNF-± levels in IFG, IGT, and MetS groups compared to healthy controls (p<0.001). The levels of IL-6 were signi cantly higher in MetS group than healthy controls (p=0.007). Conclusion: The circulating betatrophin and TNF-± levels were increased in MetS, IFG and IGT. IL-6 was decreased in MetS compared to the healty controls. Further studies are needed to elucidate the role of betatrophin and in ammatory parameters in the development of T2DM and prediabetic syndromes, whether betatrophin could have clinical applications in the development of new antidiabetic agents.
Publication Details
Page(s) 303-307
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 32, Issue: 3, Year: 2022

Request the full text from PASTIC

Keywords
Diabetes Mellitus Type 2, Metabolic syndrome, Insulin resistance, IL-6, Betatrophin, TNF-alpha
0

Citations

0

Downloads

53

Views